e-Drug3D

1530

CRIZOTINIB

INN
CRIZOTINIB

cas 877399-52-5

CLASS

ANTINEOPLASTIC AGENTS
TYROSINE KINASE INHIBITOR

ROUTE (list)

ORAL

ATC code

L01ED01

PK parameters

F 43 PERCENT (250 MILLIGRAM)
VD 1772 LITER (50 MILLIGRAM INTRAVENOUS)
Cl 60 LITER / HOUR (500 MILLIGRAM DAILY)
PPB 91 PERCENT
t1/2 42 HOUR (250 MILLIGRAM)

Solubility

IN AQUEOUS MEDIA DECREASES OVER THE RANGE PH 1.6 TO PH 8.2 FROM GREATER THAN 10 MILLIGRAM / MILLILITER TO LESS THAN 0.1 MILLIGRAM / MILLILITER

Target

TARGET TYROSINE KINASES
ALK (IC50=24 NANOMOLAR) PMID22162641
C-MET

PDB
5AAB (STRUCTURE OF C1156Y,L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB)

Ligand code = VGH (link to the list of PDB complexes)

Download experimental 3D coordinates of VGH with added hydrogens

DrugCentral

Hepatocyte growth factor receptor UNIPROT P08581 MET

ALK tyrosine kinase receptor UNIPROT Q9UM73 ALK

Download SDF file

(R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine

Formula:
C21H22Cl2FN5O

Calculated chemical properties:

MW 450.34
NB_atoms 30
XLogP 5.04
PSA 73.769
NB_HD 3
NB_HA 6
fsp3 0.33
Lipinski(0=no;1=yes) 0

FDA
NDA 202570 (label) INN (CRIZOTINIB) XALKORI (PF PRISM CV) APPROVAL= AP YEAR= 2011
NDA 217581 (label) INN (CRIZOTINIB) XALKORI (PF PRISM CV) APPROVAL= AP YEAR= 2023